1E Therapeutics has a total of 32 patents globally, out of which 2 have been granted. Of these 32 patents, more than 84% patents are active. United States of America is where 1E Therapeutics has filed the maximum number of patents, followed by Europe (EPO) and Australia. Parallelly, United States of America seems to be the main focused R&D centre and also Israel is the origin country of 1E Therapeutics.
1E Therapeutics was founded in the year 2020. 1E Therapeutics is an innovative drug development company specializing in RNA-targeting therapeutics. Using a proprietary drug design platform, they aim to revolutionize treatment options by creating cutting-edge therapies that address critical medical challenges.
Do read about some of the most popular patents of 1E Therapeutics which have been covered by us in this article and also you can find 1E Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over 1E Therapeutics patent portfolio.
How many patents does 1E Therapeutics have?
1E Therapeutics has a total of 32 patents globally. These patents belong to 6 unique patent families. Out of 32 patents, 27 patents are active.
How Many Patents did 1E Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | 1E Therapeutics Applications Filed | 1E Therapeutics Patents Granted |
| 2024 | 1 | 2 |
| 2023 | 4 | – |
| 2022 | 11 | – |
| 2021 | 16 | – |
How many 1E Therapeutics patents are Alive/Dead?
How Many Patents did 1E Therapeutics File in Different Countries?
Countries in which 1E Therapeutics Filed Patents
| Country | Patents |
| United States of America | 5 |
| Europe (EPO) | 5 |
| Australia | 5 |
| Israel | 5 |
| Korea (South) | 5 |
| Hong Kong (S.A.R.) | 1 |
Where are Research Centres of 1E Therapeutics Patents Located?
The Research Centre for all the 1E Therapeutics patents is the United States of America.
List of 1E Therapeutics Patents
| 1E Therapeutics | Title |
| US11981896B2 | P21 Mrna Target Areas For Silencing |
| US11879140B2 | P21 Mrna Targeting Dnazymes |
| US20240076671A1 | P21 Mrna Targeting Dnazymes |
| EP4384620A1 | Dnazymes Targeting Cell Wall Synthesis Enzymes And Uses Thereof |
| EP4381073A1 | Guanine-Rich Deoxyribozymes, Compositions And Uses Thereof |
| WO2024105654A1 | Methods And Compositions Including Conjugated Dnazymes |
| AU2021411103A9 | P21 Mrna Target Areas For Silencing |
| AU2021416356A9 | P21 Mrna Targeting Dnazymes |
| HK40101784A | P21 Mrna Target Areas For Silencing |
| IL310312A | Dnazymes Targeting Cell Wall Synthesis Enzymes And Uses Thereof |
| IL310313A | Guanine-Rich Deoxyribozymes, Compositions And Uses Thereof |
| AU2022325553A1 | Dnazymes Targeting Cell Wall Synthesis Enzymes And Uses Thereof |
| AU2022322003A1 | Guanine-Rich Deoxyribozymes, Compositions And Uses Thereof |
| AU2021374966A9 | Catalytic Sequence Based Methods Of Treating Or Preventing Bacterial Infections |
| KR1020240045303A | Dnazyme Targeting Cell Wall Synthesis Enzyme And Its Uses |
| KR1020240042013A | Guanine-Rich Deoxyribozyme, Compositions And Uses Thereof |
| US20230416750A1 | Catalytic Sequence Based Methods Of Treating Or Preventing Bacterial Infections |
| US20230265424A1 | Methods Of Treating And Preventing Bacterial Infections |
| EP4267741A2 | P21 Mrna Target Areas For Silencing |
| EP4267742A2 | P21 Mrna Targeting Dnazymes |
| EP4240856A2 | Catalytic Sequence Based Methods Of Treating Or Preventing Bacterial Infections |
| WO2023017501A1 | Dnazymes Targeting Cell Wall Synthesis Enzymes And Uses Thereof |
| WO2023012801A1 | Guanine-Rich Deoxyribozymes, Compositions And Uses Thereof |
| IL304068A | P21 Mrna Targeting Dnazymes |
| IL304047A | P21 Mrna Target Areas For Silencing |
| IL302594A | Catalytic Sequence Based Methods Of Treating Or Preventing Bacterial Infections |
| KR1020230133859A | P21 Mrna Targeting Dnazyme |
| KR1020230126725A | P21 Mrna Target Site For Silencing |
| KR1020230107296A | Methods For Treating Or Preventing Bacterial Infections Based On Catalytic Sequences |
| WO2022144883A3 | P21 Mrna Targeting Dnazymes |
| WO2022144882A3 | P21 Mrna Target Areas For Silencing |
| WO2022097157A3 | Catalytic Sequence Based Methods Of Treating Or Preventing Bacterial Infections |
What are 1E Therapeutics key innovation segments?
What Technologies are Covered by 1E Therapeutics?
The chart below distributes patents filed by 1E Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where 1E Therapeutics thinks it’s important to protect particular technology inventions.
R&D Focus: How has 1E Therapeutics search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by 1E Therapeutics?